Market Research Logo

Global Respiratory Drugs Market 2018-2024

Global Respiratory Drugs Market 2018-2024

Respiratory disorders, which affect mechanisms of the respiratory system such as the lungs and airway, are a wide-ranging chronic disease with a diversity of underlying causes, ranging from inherited mutations to pathological inflammation. The respiratory disorders market is dominated by long-acting beta-agonist (LABA) and long-acting muscarinic antagonist (LAMA) therapies for chronic obstructive pulmonary disease (COPD) and asthma. These drugs stimulate muscles surrounding the bronchial tubes to suppress and open the airways.

Respiratory therapy area consists of signs that affect the lungs, bronchi, trachea, larynx, pharynx and nose in various ways, such as the scarring of lung tissue or the extreme production of mucus. Respiratory disease generally results in breathing difficulties, that can lead to troubles in sleep, wheezing, anxiety, and stress. During worse condition, shortness of breath (dyspnea) can limit physical activity, affecting both the quality of life and life expectancy of sufferers. The cause of respiratory disorders contrasts significantly across each indication and comprises factors such as environment, occupation, genetic predisposition, and aging.

Report Scope:

Report Category: Pharmacuticals / Healthcare

Therapy Type
Asthma
Chronic Obstructive Pulmonary Disease
Idiopathic Pulmonary Fibrosis
Cystic Fibrosis
End-user
Hospitals
Ambulatory Care
Others
Regions
North America
Europe
Asia Pacific
Rest of the World
Industry Outlook: Market Trends and Drivers, Restraints, and Opportunities


1 Industry Outlook 9
1.1 Industry Overview 9
1.2 Total Addressable Market 10
1.3 Industry Trends 10
2 Report Outline 12
2.1 Report Scope 12
2.2 Report Summary 12
2.3 Research Methodology 13
2.4 Report Assumptions 13
3 Market Snapshot 15
3.1 Market Definition – Infoholic Research 15
3.2 Segmented Addressable Market (SAM) 15
3.3 Importance of Respiratory Care 15
3.4 Trends of Respiratory Drugs Market 16
3.5 Related Markets 17
3.5.1 Oncology (Cancer) Drugs 17
3.5.2 Active pharmaceutical ingredients (APIs) 17
3.5.3 Over the counter drugs (OTC) 18
3.5.4 Diabetes Drugs 18
4 Market Outline 20
4.1 Pipeline Products of Respiratory Drugs by Major Companies 20
4.2 Market Segmentation 23
4.3 Porter 5(Five) Forces 24
4.4 PEST Analysis 25
5 Market Characteristics 26
5.1 Market Dynamics of Respiratory Drugs Market 26
5.1.1 Drivers 27
5.1.1.1 Increasing Aging Population 27
5.1.1.2 Rising prevalence of respiratory diseases 28
5.1.1.3 High prevalence of tobacco smoking 28
5.1.2 Opportunities 28
5.1.2.1 Supportive initiatives from government and other organizations 28
5.1.2.2 Huge pool of undiagnosed chronic obstructive pulmonary disease population 28
5.1.3 Restraints 29
5.1.3.1 Expiry of patents for blockbuster drugs 29
5.1.3.2 Complex drug development process 30
5.1.4 DRO – Impact Analysis 30
5.1.5 Key Stakeholders 31
6 Application: Market Size and Analysis 33
6.1 Overview 33
6.2 Asthma 34
6.3 Chronic Obstructive Pulmonary Disease (COPD) 35
6.4 Cystic Fibrosis 36
6.5 Allergic Rhinitis 37
6.6 Others 38
7 Regions: Market Size and Analysis 40
7.1 Overview 40
7.2 North America 41
7.2.1 Overview 41
7.2.2 United States 42
7.2.3 Canada 43
7.3 Europe 43
7.3.1 Overview 43
7.3.2 United Kingdom 44
7.3.3 Germany 44
7.3.4 France 45
7.4 APAC 45
7.4.1 Overview 45
7.4.2 India 45
7.4.3 China 46
7.4.4 Japan 46
7.5 Rest of the World 47
7.5.1 Overview 47
7.5.2 Middle East 48
7.5.3 Brazil 49
7.5.4 Mexico 49
8 Competitive Landscape 50
9 Vendor Profiles 53
9.1 Novartis AG 53
9.1.1 Overview 53
9.1.2 Business Unit 58
9.1.3 Geographic Presence 58
9.1.4 Business Focus 59
9.1.5 SWOT Analysis 59
9.1.6 Business Strategy 60
9.2 GlaxoSmithKline plc 62
9.2.1 Overview 62
9.2.2 Geographic Presence 67
9.2.3 Business Focus 67
9.2.4 SWOT Analysis 68
9.2.5 Business Strategy 69
9.3 Astra Zenca PLC 71
9.3.1 Overview 71
9.3.2 Geographic Presence 76
9.3.3 Business Focus 76
9.3.4 SWOT Analysis 77
9.3.5 Business Strategy 77
9.4 F.Hoffmann-La Roche Ltd. 78
9.4.1 Overview 78
9.4.2 Business Unit 82
9.4.3 Geographic Presence 83
9.4.4 Business Focus 84
9.4.5 SWOT Analysis 84
9.4.6 Business Strategy 85
9.5 Vertex Pharmaceuticals Inc. 86
9.5.1 Overview 86
9.5.2 Geographic Presence 89
9.5.3 Business Focus 89
9.5.4 SWOT Analysis 90
9.5.5 Business Strategy 90
10 Companies to Watch For 92
10.1 Boehringer Ingelheim GmbH 92
10.1.1 Overview 92
10.1.2 Highlights 93
10.2 Teva Pharmaceutical Industries Ltd. 94
10.2.1 Overview 94
10.2.2 Highlights: 96
10.3 Gilead Sciences Inc. 96
10.3.1 Overview 96
10.3.2 Highlights: 98
10.4 Bayer AG 99
10.4.1 Overview 99
10.5 Pfizer Inc. 101
10.5.1 Overview 101
10.5.2 Highlights 103
10.6 Bristol-Myers Squibb Co. 104
10.6.1 Overview 104
10.7 Merck & Co. 106
10.7.1 Overview 106
10.7.2 Highlights: 107
10.8 Sanofi 108
10.8.1 Overview 108
10.9 Mallinckrodt plc 109
10.9.1 Overview 109
Annexure 111
Abbreviations 111
Tables
TABLE 1 RESPIRATORY DRUGS: PIPELINE PRODUCTS 20
TABLE 2 PATENT EXPIRATION OF RESPIRATORY DRUGS 28
TABLE 3 RESPIRATORY DRUGS MARKET REVENUE BY APPLICATION, 2017–2024 ($MILLION) 31
TABLE 4 RESPIRATORY DRUGS MARKET REVENUE BY REGIONS, 2017–2024 ($MILLION) 39
TABLE 5 MAJOR RESPIRATORY DRUGS MARKET ($MILLION) 49
TABLE 6 NOVARTIS AG: OFFERINGS 51
TABLE 7 NOVARTIS AG: RECENT DEVELOPMENTS 52
TABLE 8 NOVARTIS AG RESPIRATORY DRUGS PIPELINE MOLECULES 56
TABLE 9 GLAXOSMITHKLINE PLC: OFFERINGS 58
TABLE 10 GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS 59
TABLE 11 ASTRA ZENCA PLC: OFFERINGS 66
TABLE 12 ASTRA ZENCA PLC: RECENT DEVELOPMENTS 68
TABLE 13 F. HOFFMANN-LA ROCHE LTD.: OFFERINGS 73
TABLE 14 F. HOFFMANN-LA ROCHE LTD.: RECENT DEVELOPMENTS 74
TABLE 15 ROCHE: PIPELINE MOLECULES IN RESPIRATORY DRUGS SEGMENT 78
TABLE 16 VERTEX PHARMACEUTICALS INC.: OFFERINGS 80
TABLE 17 VERTEX PHARMACEUTICALS INC.: RECENT DEVELOPMENTS 80
TABLE 18 VERTEX PHARMACEUTICALS: PIPELINE MOLECULES IN RESPIRATORY DRUGS SEGMENT 84
TABLE 19 BOEHRINGER INGELHEIM GMBH: OVERVIEW 86
TABLE 20 TEVA PHARMACEUTICAL INDUSTRIES LTD.: OVERVIEW 88
TABLE 21 GILEAD SCIENCES INC.: OVERVIEW 89
TABLE 22 BAYER AG: OVERVIEW 91
TABLE 23 BAYER AG: RECENT DEVELOPMENTS 91
TABLE 24 PFIZER INC. OVERVIEW 93
TABLE 25 PFIZER INC.: RECENT DEVELOPMENTS 93
TABLE 26 BRISTOL-MYERS SQUIBB CO.: OVERVIEW 95
TABLE 27 BRISTOL-MYERS SQUIBB CO.: KEY DEVELOPMENTS 95
TABLE 28 MERCK & CO.: OVERVIEW 97
TABLE 29 MERCK & CO.: RECENT DEVELOPMENTS 97
TABLE 30 SANOFI: OVERVIEW 99
TABLE 31 SANOFI: RECENT DEVELOPMENTS 99
TABLE 32 MALLINCKRODT PLC: OVERVIEW 100
Charts
CHART 1 RESEARCH METHODOLOGY OF GLOBAL RESPIRATORY DRUGS MARKET
CHART 2 GLOBAL RESPIRATORY DRUGS MARKET REVENUE, 2017-2024 ($MILLION)
CHART 3 SEGMENTATION OF GLOBAL REPIRATORY DRUGS MARKET
CHART 4 PORTER 5 FORCES OF RESPIRATORY DRUGS MARKET
CHART 5 PEST ANALYSIS OF REPIRATORY DRUGS MARKET
CHART 6 MARKET DYNAMICS – DRO ANALYSIS
CHART 7 WORLD POPULATION AGED 65 YEARS AND ABOVE, 1960-2060 (%)
CHART 8 DRO – IMPACT ANALYSIS OF GLOBAL RESPIRATORY DRUGS MARKET
CHART 9 KEY STAKEHOLDERS
CHART 10 RESPIRATORY DRUGS MARKET BY APPLICATION SEGMENTATION, 2017 VS 2024 (%)
CHART 11 RESPIRATORY DRUGS MARKET REVENUE IN ASTHMA APPLICATION, 2017-2024 ($MILLION)
CHART 12 RESPIRATORY DRUGS MARKET REVENUE IN COPD APPLICATION, 2017-2024 ($MILLION)
CHART 13 RESPIRATORY DRUGS MARKET REVENUE IN CYSTIC FIBROSIS APPLICATION, 2017-2024 ($MILLION)
CHART 14 RESPIRATORY DRUGS MARKET REVENUE IN ALLERGIC RHINITIS APPLICATION, 2017-2024 ($MILLION)
CHART 15 RESPIRATORY DRUGS MARKET REVENUE IN OTHERS APPLICATION, 2017-2024 ($MILLION)
CHART 16 RESPIRATORY DRUGS MARKET BY REGIONAL SEGMENTATION, 2017 VS 2024 (%)
CHART 17 RESPIRATORY DRUGS MARKET REVENUE IN NORTH AMERICA, 2017-2024 ($MILLION)
CHART 18 RESPIRATORY DRUG MARKET REVENUE IN THE EUROPE REGION, 2017–2023 ($MILLION)
CHART 19 RESPIRATORY DRUGS MARKET REVENUE IN THE APAC REGION, 2017-2024 ($MILLION)
CHART 20 RESPIRATORY DRUGS MARKET REVENUE IN REST OF THE WORLD, 2017–2024 ($MILLION)
CHART 21 RESPIRATORY PIPELINE DRUGS IN THE MARKET
CHART 22 MARKET SHARE OF MAJOR PLAYERS-2017 (%)
CHART 23 NOVARTIS AG: OVERVIEW SNAPSHOT
CHART 24 NOVARTIS AG: BUSINESS UNITS
CHART 25 NOVARTIS AG: GEOGRAPHICAL PRESENCE
CHART 26 NOVARTIS AG: SWOT ANALYSIS
CHART 27 GLAXOSMITHKLINE PLC: OVERVIEW SNAPSHOT
CHART 28 GLAXOSMITHKLINE PLC: BUSINESS UNITS
CHART 29 GLAXOSMITHKLINE PLC: GEOGRAPHIC PRESENCE
CHART 30 GSK: REVENUE OF RESPIRATORY PORTFOLIO
CHART 31 GLAXOSMITHKLINE PLC: SWOT ANALYSIS
CHART 32 ASTRA ZENCA PLC: OVERVIEW SNAPSHOT
CHART 33 ASTRA ZENCA PLC: BUSINESS UNITS
CHART 34 ASTRA ZENCA PLC: GEOGRAPHIC PRESENCE
CHART 35 ASTRA ZENCA PLC: SWOT ANALYSIS
CHART 36 F. HOFFMANN-LA ROCHE LTD.: OVERVIEW SNAPSHOT
CHART 37 F. HOFFMANN.LA ROCHE LTD.: BUSINESS UNITS
CHART 38 F. HOFFMANN-LA ROCHE: GEOGRAPHICAL PRESENCE
CHART 39 F. HOFFMANN-LA ROCHE LTD.: SWOT ANALYSIS
CHART 40 VERTEX PHARMACEUTICALS INC.: OVERVIEW SNAPSHOT
CHART 41 VERTEX PHARMACEUTICALS INC.: GEOGRAPHICAL PRESENCE
CHART 42 VERTEX PHARMACEUTICALS INC.: SWOT ANALYSIS

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report